These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38684041)
1. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041 [TBL] [Abstract][Full Text] [Related]
2. Seizures in patients with IDH-mutated lower grade gliomas. Carstam L; Rydén I; Jakola AS J Neurooncol; 2022 Nov; 160(2):403-411. PubMed ID: 36258151 [TBL] [Abstract][Full Text] [Related]
3. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis. Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320 [TBL] [Abstract][Full Text] [Related]
4. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877 [TBL] [Abstract][Full Text] [Related]
5. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895 [TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
8. Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging. Noble Anbunesan S; Alfonso-Garcia A; Zhou X; Bec J; Lee HS; Jin LW; Bloch O; Marcu L J Biophotonics; 2023 Apr; 16(4):e202200291. PubMed ID: 36510639 [TBL] [Abstract][Full Text] [Related]
9. Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study. van der Vaart T; Wijnenga MMJ; van Garderen K; Dubbink HJ; French PJ; Smits M; Dirven CMF; Kros JM; Vincent AJPE; van den Bent MJ Clin Cancer Res; 2024 Sep; 30(17):3837-3844. PubMed ID: 38990096 [TBL] [Abstract][Full Text] [Related]
10. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414 [TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510 [TBL] [Abstract][Full Text] [Related]
17. Rare dual-genotype IDH mutant glioma: Review of previously reported cases and two new cases of true "oligoastrocytoma". Sutherland I; DeWitt J; Thomas A Neuropathology; 2024 Oct; 44(5):401-407. PubMed ID: 38581197 [TBL] [Abstract][Full Text] [Related]
18. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Stockhammer F; Misch M; Helms HJ; Lengler U; Prall F; von Deimling A; Hartmann C Seizure; 2012 Apr; 21(3):194-7. PubMed ID: 22217666 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640 [TBL] [Abstract][Full Text] [Related]
20. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]